Glyceryl tris(beta-hydroxybutyrate) and neuronal transient ischemic attacks

A technology of transient cerebral ischemia and hydroxybutyrate used in the fields of medical food, nutritional supplements and pharmaceuticals

Pending Publication Date: 2021-11-26
NEUROENERGY VENTURES INC
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Separate and distinct NTIAs that are clearly separated in time may not lead to cumulative effects, especially if the affected cells are already able to heal, but multiple NTIAs over a relatively short period of time (days-weeks-months) Sub-NTIAs can and often lead to cumulative effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Embodiment 1 Invention Implementation Mode

[0034] The first 60 kg female subject (Day 0) was found to have NTIA and was started on an oral regimen of GTβHB 40 g / dose, 3 times daily starting on the following day (Day 1). Two days later (Day 3), the subject suffered a further NTIA and continued to take GTβHB for the next 55 days.

Embodiment 2

[0035] Embodiment 2 is not the comparative embodiment of the present invention

[0036] A second 60 kg female subject (day zero) was also found to have NTIA, but did not start any GTβHB administration. Further NTIA occurred on day 3 (2 days later). Subjects did not initiate any GTβHB administration.

Embodiment 3

[0037] Embodiment 3 Invention Implementation Mode

[0038] A third 60 kg female subject (day zero) was also found to have NTIA, but did not start any GTβHB administration. Further NTIA occurred on day 3 (2 days later). Subjects then started an oral regimen of GTβHB 40 g / dose, 3 times daily starting on the following day (Day 4) and continued the regimen for the next 54 days (until Day 60).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A method of use of glyceryl tris(beta-hydroxybutyrate) in the minimization, reduction, or prevention of neuronal deficit and / or neuronal cell death with respect to follow-on neuronal transient ischemic attacks (NTIAs) in subjects who have had (or in subjects exhibiting symptomology of having had) at least one prior NTIA is disclosed by the invention.

Description

[0001] Cross References to Related Applications [0002] Not applicable. [0003] Statement Regarding Federally Sponsored Research or Development [0004] Not applicable. technical field [0005] This application relates to the field of medical foods, nutritional supplements and pharmaceuticals. The present invention also relates to the use of triglyceride (beta-hydroxybutyrate), which is also called tributyrin but hereinafter referred to as GTβHB. The present invention also relates to modalities to help manage the sequelae of neuronal transient ischemic attack (hereinafter referred to as NTIA), nutritional supplements, medical foods and medicines for prophylactically treating the sequelae of NTIA, or diets in NTIA Any one of the above areas of management. The present invention further relates to prophylactic enteral administration of GTβHB prior to further NTIA for use in helping to reduce or eliminate NTIA-related neurological deficits and / or reduce or eliminate modaliti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/22C07C69/675A61P25/00
CPCA61K31/22A61P25/00A61P25/28
Inventor 萨米·哈希姆
Owner NEUROENERGY VENTURES INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products